PL3654989T3 - Zastosowanie kladrybiny do leczenia autoimmunologicznej choroby nerwowo-mięśniowej - Google Patents
Zastosowanie kladrybiny do leczenia autoimmunologicznej choroby nerwowo-mięśniowejInfo
- Publication number
- PL3654989T3 PL3654989T3 PL18739593.4T PL18739593T PL3654989T3 PL 3654989 T3 PL3654989 T3 PL 3654989T3 PL 18739593 T PL18739593 T PL 18739593T PL 3654989 T3 PL3654989 T3 PL 3654989T3
- Authority
- PL
- Poland
- Prior art keywords
- nervousculatory
- cladribine
- autoimmune
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1711800.1A GB2564717A (en) | 2017-07-21 | 2017-07-21 | Use of cladribine for treating autoimmune neuromuscular disease |
| PCT/GB2018/051801 WO2019016505A1 (en) | 2017-07-21 | 2018-06-28 | USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3654989T3 true PL3654989T3 (pl) | 2024-05-20 |
Family
ID=59771723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18739593.4T PL3654989T3 (pl) | 2017-07-21 | 2018-06-28 | Zastosowanie kladrybiny do leczenia autoimmunologicznej choroby nerwowo-mięśniowej |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12171775B2 (enExample) |
| EP (2) | EP3654989B1 (enExample) |
| JP (1) | JP7186214B2 (enExample) |
| CA (1) | CA3095893A1 (enExample) |
| DK (1) | DK3654989T3 (enExample) |
| ES (1) | ES2974423T3 (enExample) |
| FI (1) | FI3654989T3 (enExample) |
| GB (1) | GB2564717A (enExample) |
| HR (1) | HRP20240282T1 (enExample) |
| HU (1) | HUE066238T2 (enExample) |
| LT (1) | LT3654989T (enExample) |
| PL (1) | PL3654989T3 (enExample) |
| PT (1) | PT3654989T (enExample) |
| RS (1) | RS65246B1 (enExample) |
| SI (1) | SI3654989T1 (enExample) |
| WO (1) | WO2019016505A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
| AU2024399689A1 (en) | 2023-12-14 | 2026-07-30 | Ares Trading S.A. | Cladribine regimen for treating myasthenia gravis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| AU6234000A (en) * | 1999-07-22 | 2001-02-13 | Supergen, Inc. | Methods for treating autoimmune diseases |
| AU2003286836A1 (en) * | 2002-10-31 | 2004-06-07 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| EP1567945A2 (en) * | 2002-11-22 | 2005-08-31 | Transclick, Inc. | System and method for speech translation using remote devices |
| ES2584183T3 (es) | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| PL2805723T3 (pl) * | 2004-12-22 | 2018-04-30 | Merck Serono Sa | Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego |
| MX2008014971A (es) * | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
-
2017
- 2017-07-21 GB GB1711800.1A patent/GB2564717A/en not_active Withdrawn
-
2018
- 2018-06-28 PT PT187395934T patent/PT3654989T/pt unknown
- 2018-06-28 PL PL18739593.4T patent/PL3654989T3/pl unknown
- 2018-06-28 LT LTEPPCT/GB2018/051801T patent/LT3654989T/lt unknown
- 2018-06-28 JP JP2020502477A patent/JP7186214B2/ja active Active
- 2018-06-28 WO PCT/GB2018/051801 patent/WO2019016505A1/en not_active Ceased
- 2018-06-28 EP EP18739593.4A patent/EP3654989B1/en active Active
- 2018-06-28 SI SI201831074T patent/SI3654989T1/sl unknown
- 2018-06-28 EP EP23205297.7A patent/EP4292663A3/en active Pending
- 2018-06-28 FI FIEP18739593.4T patent/FI3654989T3/fi active
- 2018-06-28 US US16/632,245 patent/US12171775B2/en active Active
- 2018-06-28 HR HRP20240282TT patent/HRP20240282T1/hr unknown
- 2018-06-28 HU HUE18739593A patent/HUE066238T2/hu unknown
- 2018-06-28 RS RS20240253A patent/RS65246B1/sr unknown
- 2018-06-28 ES ES18739593T patent/ES2974423T3/es active Active
- 2018-06-28 CA CA3095893A patent/CA3095893A1/en active Pending
- 2018-06-28 DK DK18739593.4T patent/DK3654989T3/da active
-
2024
- 2024-11-14 US US18/948,158 patent/US20250302858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20240282T1 (hr) | 2024-05-10 |
| EP3654989B1 (en) | 2024-01-03 |
| GB201711800D0 (en) | 2017-09-06 |
| EP4292663A3 (en) | 2024-03-20 |
| US20200163986A1 (en) | 2020-05-28 |
| PT3654989T (pt) | 2024-02-28 |
| US20250302858A1 (en) | 2025-10-02 |
| US12171775B2 (en) | 2024-12-24 |
| FI3654989T3 (fi) | 2024-03-21 |
| WO2019016505A1 (en) | 2019-01-24 |
| GB2564717A (en) | 2019-01-23 |
| DK3654989T3 (da) | 2024-02-26 |
| EP3654989A1 (en) | 2020-05-27 |
| LT3654989T (lt) | 2024-03-25 |
| SI3654989T1 (sl) | 2024-06-28 |
| ES2974423T3 (es) | 2024-06-27 |
| HUE066238T2 (hu) | 2024-07-28 |
| RS65246B1 (sr) | 2024-03-29 |
| JP2020527156A (ja) | 2020-09-03 |
| EP4292663A2 (en) | 2023-12-20 |
| CA3095893A1 (en) | 2019-01-24 |
| JP7186214B2 (ja) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| IL262092A (en) | Humanized anti-pacap antibodies and uses thereof | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| IL256687B (en) | Isolated tau-binding antibody and use thereof in therapy and diagnosis | |
| LT3240554T (lt) | Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| IL251530B (en) | Use of cannabinoids in the treatment of degenerative skeletal muscle diseases | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| HUE062189T2 (hu) | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| DK3474802T3 (da) | Medicinsk forbinding | |
| PL3386531T3 (pl) | Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów | |
| IL258259A (en) | Adjunctive therapy with 25-hydroxyvitamin d and articles therefor | |
| HRP20180260T1 (hr) | Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| EP3445431A4 (en) | PATIENT INTERFACE AND ASPECTS THEREOF | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| MA50358A (fr) | Sémaglutide en thérapie médicale | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii |